After the announcement of the US FDA to the go-ahead for the recall, for those who have done a dose of Johnson & Johnson, with Moderna, Italy is now preparing for the new administrations. This is confirmed by the president of the Superior Health Council and coordinator of the scientific technical committee Franco Locatelli.
"The Johnson & Johnson vaccine is one of the adenoviral vector vaccines, like that of Astrazeneca, single-dose - recalled Locatelli yesterday, guest of the show" Che tempo che fa "on Rai3 -. It is at this time that the news is in progress that a review process is underway by the FDA and subsequently there will certainly also be Ema, if indications arrive, as is widely possible, to administer a second dose ".
The hypothesis is, also for Italy, that of a "heterologous" vaccine, and therefore a second dose with Pfizer or Moderna, "messenger RNA" vaccines that would have "the advantage of generating an even better immunological response", Locatelli specified.
According to the studies presented by the company and accepted by the American and EU regulatory bodies, the effectiveness of the Johnson & Johnson vaccine on over 18s is about 72 percent - which however rises to 100 percent in contrasting any serious forms of the disease - against 94-95 percent of messenger RNA vaccines. Hence the choice of the heterologous booster, a bit as recommended to those who have been inoculated with AstraZeneca, which is important for reinforcing the efficacy and immune response.
(Unioneonline / vl)
